Skip to main content
Fig. 5 | Molecular Cancer

Fig. 5

From: LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes

Fig. 5

PVT1 directly targets miR-619-5p. a and b Potential miRNAs that target both Pygo2 and PVT1 were predicted using the miRWalk and TargetScan databases. c The expression of predicted miRNAs that target both Pygo2 and PVT1 was assessed by qRT-PCR after PVT1 transfected with siRNA for 48 h. Heatmap were drawn by using ImageGP online software (http://www.ehbio.com/ImageGP/). d and e The expression of miR-619-5p was measured in PANC-1 cells treated with indicated concentration and time. f The predicted miR-619-5p binding sequence in PVT1 and the generation of dual-luciferase reporter plasmids of wild-type (WT) or mutant (MT) were shown. g Luciferase activity assays were performed in HEK293T or PANC-1 cells co-transfected with PVT1 WT or PVT1 MT and miR-NC or miR-619-5p. h Luciferase activity assays were performed in HEK293T or PANC-1 cells co-transfected with PVT1 WT or PVT1 MT and miR-619-5p inhibitor or inhibitor-NC. i The relative expression of miR-619-5p in PANC-1 and ASPC-1 cells transfected with PVT1 siRNA or PVT1 overexpression plasmid. j The relative expression of PVT1 in PANC-1 and ASPC-1 cells transfected with miR-619-5p mimics. k and l Anti-Ago2 RIP was performed in PANC-1 and ASPC-1 cells transfected with miR-619-5p mimics or miR-NC, followed by qRT-PCR to detect PVT1 enrichment. Data were represented as mean ± SD, *P < 0.05; **P < 0.01; ***P < 0.001

Back to article page